Brendan Christian Bender

Title: Brendan Christian Bender: Innovator in Bispecific Antibody Treatments

Introduction

Brendan Christian Bender is a notable inventor based in South San Francisco, CA. He has made significant contributions to the field of medical treatments, particularly in the area of bispecific antibodies. His work focuses on innovative solutions for treating CD20-positive cell proliferative disorders.

Latest Patents

Brendan holds a patent for "Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies." This invention relates to the treatment of subjects with CD20-positive cell proliferative disorders, such as non-Hodgkin's lymphomas. The patent specifically addresses the intravenous administration of an anti-CD20/anti-CD3 bispecific antibody, exemplified by mosunetuzumab. He has 1 patent to his name.

Career Highlights

Brendan is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His role at Genentech allows him to work on cutting-edge therapies that have the potential to improve patient outcomes in oncology.

Collaborations

Throughout his career, Brendan has collaborated with esteemed colleagues, including Chi-Chung Li and Carol Elaine O'hear. These partnerships have fostered a collaborative environment that enhances the development of new therapeutic strategies.

Conclusion

Brendan Christian Bender is a prominent figure in the field of bispecific antibody treatments, with a focus on addressing critical medical needs. His innovative patent and work at Genentech highlight his commitment to advancing healthcare solutions.